Arun V. Ravindran, MD, PhD

  • 9Articles
  • 54.6KReads
  • 1997–2022Active
  • 75Collaborators
  • 353Citations

About

Arun V. Ravindran, MD, PhD, is affiliated with the Centre for Addiction and Mental Health and the Department of Psychiatry at the University of Toronto. With publications spanning from 1997 to 2022, Ravindran has contributed extensively to clinical research on major depressive disorder, including treatment-resistant depression, comorbid anxiety disorders, and dysthymia. His work also addresses the impact of weight and sex-specific factors in depression, with studies on pharmacologic treatments such as quetiapine, aripiprazole, escitalopram, paroxetine, and methylphenidate. He has frequently collaborated with researchers including Sidney H. Kennedy and Claudio N. Soares.

Publications

JCP
Quetiapine XR in Comorbid Depression and Anxiety
Original Research

Quetiapine XR in Comorbid Depression and Anxiety

March 21, 2022

Quetiapine is often used off-label for anxiety and as an augmentation agent in treatment-resistant depression. This study evaluated the efficacy and tolerability of quetiapine in augmenting first-line antidepressants for...
, , , et al
JCP
Original Research

Interest-Activity Levels and Need for AD Augmentation in MDD

June 16, 2020

Depressed people who have lost interest and are inactive may not respond well to antidepressants. This study examined whether depressed subjects with low interest and activity who responded poorly...
, , , et al
JCP
Original Research

CAN-BIND-1 Outcomes and Early Response Prediction in MDD

February 5, 2019

Antidepressant medications are often prescribed with little certainty about their potential effectiveness in individual patients. Can early symptom reduction help predict later symptomatic and functional outcomes of antidepressant treatment?...
, , , et al
JCP
Review Article

Comparative Efficacy, Acceptability, and Tolerability of Augmentation Agents in Treatment-Resistant Depression: Systematic Review and Network Meta-Analysis

April 22, 2015

, , , et al
JCP
Original Research

Obesity Comorbidity in Unipolar Major Depressive Disorder: Refining the Core Phenotype

May 15, 2012

, , , et al
JCP
Article

Luteal Phase Administration of Paroxetine for the Treatment of Premenstrual Dysphoric Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women

June 30, 2008

, , , et al
JCP
Original Research

Osmotic-Release Oral System Methylphenidate Augmentation of Antidepressant Monotherapy in Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Trial

January 15, 2008

, , , et al
JCP
Original Research

Treatment of Dysthymia With Sertraline: A Double-Blind, Placebo-Controlled Trial in Dysthymic Patients Without Major Depression

October 31, 2000

, , , et al
JCP
Original Research

A Double-Blind, Multicenter Study in Primary Care Comparing Paroxetine and Clomipramine in Patients With Depression and Associated Anxiety

March 15, 1997

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe